The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Neurologic Emergencies in Cancer Patients
Neurol Clin 16:1-37, Schiff,D.,et al, 1998
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Lambert-Eaton Myasthenic Syndrome (LEMS) in Association with Lymphoproliferative Disorders
Muscle & Nerve 18:715-719995., Argov,Z.,et al, 1995
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
The Remote Effects of Cancer on the Nervous System
in Neurol Manif of Systemic Dis, W. B. Saunders, Co, Phila, Neurologic Clinics 7:579-603, Dropcho,E.J., 1989
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975